Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 1
1997 1
2003 3
2004 2
2005 2
2006 3
2007 2
2008 3
2009 2
2010 3
2011 8
2012 4
2013 2
2014 4
2015 7
2016 4
2017 6
2018 14
2019 19
2020 27
2021 16
Text availability
Article attribute
Article type
Publication date

Search Results

115 results
Results by year
Filters applied: . Clear all
Page 1
A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update.
Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, Yoshiji H, Yatsuhashi H, Shimizu M, Torimura T, Moriyama M, Sakaida I, Okada H, Chiba T, Chuma M, Nakao K, Isomoto H, Sasaki Y, Kaneko S, Masaki T, Chayama K, Koike K. Tateishi R, et al. Among authors: chuma m. J Gastroenterol. 2019 Apr;54(4):367-376. doi: 10.1007/s00535-018-1532-5. Epub 2018 Nov 29. J Gastroenterol. 2019. PMID: 30498904 Free PMC article.
Diphenhydramine may be a preventive medicine against cisplatin-induced kidney toxicity.
Hamano H, Ikeda Y, Goda M, Fukushima K, Kishi S, Chuma M, Yamashita M, Niimura T, Takechi K, Imanishi M, Zamami Y, Horinouchi Y, Izawa-Ishizawa Y, Miyamoto L, Ishizawa K, Fujino H, Tamaki T, Aihara KI, Tsuchiya K. Hamano H, et al. Among authors: chuma m. Kidney Int. 2021 Apr;99(4):885-899. doi: 10.1016/j.kint.2020.10.041. Epub 2020 Dec 9. Kidney Int. 2021. PMID: 33307103
Proton pump inhibitors block iron absorption through direct regulation of hepcidin via the aryl hydrocarbon receptor-mediated pathway.
Hamano H, Niimura T, Horinouchi Y, Zamami Y, Takechi K, Goda M, Imanishi M, Chuma M, Izawa-Ishizawa Y, Miyamoto L, Fukushima K, Fujino H, Tsuchiya K, Ishizawa K, Tamaki T, Ikeda Y. Hamano H, et al. Among authors: chuma m. Toxicol Lett. 2020 Jan;318:86-91. doi: 10.1016/j.toxlet.2019.10.016. Epub 2019 Oct 24. Toxicol Lett. 2020. PMID: 31669099
Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma.
Chuma M, Uojima H, Numata K, Hidaka H, Toyoda H, Hiraoka A, Tada T, Hirose S, Atsukawa M, Itokawa N, Arai T, Kako M, Nakazawa T, Wada N, Iwasaki S, Miura Y, Hishiki S, Nishigori S, Morimoto M, Hattori N, Ogushi K, Nozaki A, Fukuda H, Kagawa T, Michitaka K, Kumada T, Maeda S. Chuma M, et al. Cancers (Basel). 2020 Jan 26;12(2):293. doi: 10.3390/cancers12020293. Cancers (Basel). 2020. PMID: 31991869 Free PMC article.
The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study.
Nozaki A, Atsukawa M, Kondo C, Toyoda H, Chuma M, Nakamuta M, Uojima H, Takaguchi K, Ikeda H, Watanabe T, Ogawa S, Itokawa N, Arai T, Hiraoka A, Asano T, Fujioka S, Ikegami T, Shima T, Ogawa C, Akahane T, Shimada N, Fukunishi S, Abe H, Tsubota A, Genda T, Okubo H, Mikami S, Morishita A, Moriya A, Tani J, Tachi Y, Hotta N, Ishikawa T, Okanoue T, Tanaka Y, Kumada T, Iwakiri K, Maeda S; KTK49 Liver Study Group. Nozaki A, et al. Among authors: chuma m. Hepatol Int. 2020 Mar;14(2):225-238. doi: 10.1007/s12072-020-10019-z. Epub 2020 Mar 3. Hepatol Int. 2020. PMID: 32128704
Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection.
Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Tanaka Y, Iwakiri K, Kumada T. Toyoda H, et al. Among authors: chuma m. J Gastroenterol Hepatol. 2020 May;35(5):855-861. doi: 10.1111/jgh.14874. Epub 2019 Nov 19. J Gastroenterol Hepatol. 2020. PMID: 31609495 Clinical Trial.
Increased Arbekacin Clearance in Patients With Febrile Neutropenia.
Nakayama T, Chuma M, Tochikura N, Iwabuchi S, Suzuki S, Matsumoto C, Imai T, Hamada T, Nakagawa M, Takahashi H, Uchino Y, Miura K, Iriyama N, Hatta Y, Takei M, Kimura T. Nakayama T, et al. Among authors: chuma m. Ther Drug Monit. 2020 Feb;42(1):133-138. doi: 10.1097/FTD.0000000000000678. Ther Drug Monit. 2020. PMID: 31323015
115 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page